24 Briefly, CFSE-labeled or nonlabeled PBMCs, PBMC-Treg, and PBMC-Treg+Treg were incubated in RPMI containing 10% FCS plus soluble anti-CD3 (1 μg/mL) PD-0332991 in vitro and anti-CD28 (1 μg/mL) for 48 hours or 96 hours. The cells were then stimulated with brefeldin A (10 μg/mL) for an additional 5 hours. The cells were then washed, stained for surface markers (CD3 and CD4) and intracellular GzmA, GzmB and perforin, and analyzed by flow cytometry. Data were analyzed with SPSS v. 13.0 for Windows software (Chicago, IL) and expressed as mean ± standard deviation (SD) for percentages. The Mann-Whitney U test, Kruskal-Wallis H test, and Wilcoxon signed ranks test were used to compare groups. Actuarial

survival rates were analyzed by the Kaplan-Meier method and survival was measured in weeks from diagnosis to death or the last review for the patients who did not receive any antitumor therapy from diagnosis to death. Disease-free survival (DFS) was measured in months from resection to tumor recurrence GPCR Compound Library datasheet or the last observation. The overall survival (OS) was measured in months from resection to death or the last review. The log-rank test was applied for comparisons between groups.

Multivariate analysis of prognostic factors for OS was made using Cox’s proportional hazards model.24, 28 P < 0.05 was considered significant. The clinical data of the HCC patients are shown in Table 1. All of the HCC patients had a history of more than 20 years of chronic HBV infection and had been hospitalized or followed up in Beijing 302 Hospital, China. No patients had received anticancer therapy prior to sampling. The median survival duration was 10.5 weeks (range, 0.75 to 29.5 weeks) for HCC patients with stage III disease, 22 months (range, 1.8 to 63 months) check details for DFS in HCC patients with stage I and II when circulating CD4+ CTLs were used as an identification

marker, and 55 months (range, 1.8 to 116 months) for both DFS and OS in HCC patients when intratumoral CD4+ CTLs were used as an identification marker. CD4+ CTLs are defined as a population of CD4+ T cells that express GzmA, GzmB, and perforin (Fig. 1A). It was found that the percentages of circulating CD4+ CTLs were significantly higher in HCC patients than in CHB and LC patients and NC subjects (Fig. 1A,B). There was no significant difference in the CD4+ CTL percentages among NC subjects and CHB and LC patients (Fig. 1B). Notably, we found that the proportion of CD4+ CTLs progressively decreased in HCC patients with advanced stage compared with those in early stages (Fig. 1C). These results indicate that a numerical decrease in CD4+ CTLs is associated with the progression of HCC. We then found that the percentage of CD4+ CTLs in TILs was lower than in NILs, and also gradually decreased in both TILs and NILs in HCC patients from stage I, stage II to stage III (Fig. 2A,B).